List of Implants Companies in United States - 237

4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR). We are the first transcatheter MR therapy that directly addresses mitral regurgitation without replacing the native mitral valve, thus preserving the native mitral annulus and left ventricle. The device is positioned supra annular to the leaking native mitral valve to stop the leak from entering the left atrium. Its atrial only fixation ensures minimal disruption to critical cardiac structures within the left ventricle including the chordae tendineae and the left ventricular outflow tract. Our initial focus is to develop a novel therapy for mitral regurgitation (MR), and subsequently for tricuspid regurgitation (TR).

Based in Danvers, Massachusetts, USA, Abiomed, Inc., part of Johnson & Johnson MedTech, is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit www.abiomed.com. Important Safety Info: https://bit.ly/39kvb47

Actuated Medical has quickly emerged as a leader in the design and development of medical devices and components. Using proprietary actuation technologies, our innovations address a wide variety of medical challenges ranging from clearing occlusions to easing tissue penetration to enabling MRI assisted procedures. From start to finish, our team designs, develops and manufactures under an ISO-certified quality control system. In addition, we continually seek feedback from domain experts to ensure our products not only solve real problems but also are readily accepted by clinicians. With a proven track record of receiving federal grants to support research and development, the company has built a successful business model that takes medical devices from conception to regulatory approval to market.

Adient Medical is a medical devices company that specializes in absorbable devices that automatically vanish, eliminating the need for removal procedures.

Advanced Bifurcation Systems Inc. has developed a novel technology to enable effective stenting of coronary arteries at their branch points (bifurcations). This comprehensive platform is a paradigm shift in interventional cardiology that will reduce the need for open-heart surgery, hospitalizations, and repeat coronary angioplasties. The technology will simplify procedures and improve outcomes while reducing angioplasty times which results in significant improvement to the overall patient care at a reduced cost.

AB is proud to be the only U.S. based manufacturer of cochlear implants and equally proud to be a part of the larger Sonova group. At AB, success begins with a passion for hearing restoration and is driven by our global workforce of over a thousand employees. For more than 25 years, AB has removed limitations for those otherwise isolated from the world of sound. Always focused on bringing meaningful change through innovative technology, AB has set the standard for performance, lifestyle support, and access to sound in the field of cochlear implantation. Having implanted over 100,000 ears in over 130 countries and established a track record for developing high-performing, state-of-the-art products, our team of talented scientists, engineers, audiologists and other professionals are driven to succeed, work with integrity, and stay firmly committed to quality. Sonova companies include brands focused on hearing aids, cochlear implants, wireless communications, and clinical service. Together, we strive to create a world where everyone enjoys the delight of hearing and lives a life without limitations.Advanced Bionics is a global leader providing solutions for severe-to-profound hearing loss.

With a complete platform of core trauma and extremity products, AOS has become a trusted leader with its entire focus on the orthopaedic trauma industry. Relying on the professional guidance of the four original founding partners, as well as the clinical expertise and training of skilled surgeon champions, AOS designs and manufactures innovative orthopaedic trauma products with intra-operative and postoperative clinical benefits. AOS’s products are distributed worldwide through independent distributors and agents. By continuing to build strong relationships with our valued distribution network and surgeon users, AOS continues to improve every aspect of the way we do business. Especially for our patients and their families worldwide.

Alafair Biosciences is a privately-held, commercial-stage medical device company focused on the development of novel clinical products using its proprietary hydrogel technology. With a patent portfolio covering a broad range of clinical applications, Alafair is focused on building a robust product pipeline. Its products are distributed through a dispersed network of independent distributors across the United States.

Alessa Therapeutics is a biotechnology company that specializes in developing localized treatments for solid organ disease.

Alleviant Medical is a medical device company developing next-generation therapies for heart failure.

Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and over 1,000,000kg lost worldwide.

Aloe Therapeutics is a biotech start-up aimed at delivering cancer cures. We have designed a therapy, termed Allo-Immunotherapy (AIM), to trigger an influx of activated immune cells to traffic to the tumor microenvironment - turning "cold" tumors "hot" and "hot" tumors "hotter." INFLAME WITH AIM.

Alpha Medical Instruments,developer, manufacturer, Balloon flotation catheters, venous catherization, right heart, measurements, venous, pulmonary artery pressures, cardiac output

The mission of Alume Biosciences is to make our proprietary nerve illumination technology available for surgeons so that patients everywhere can benefit. Learn how you can help us move surgery into the light.

Amend Surgical leads the biopharmaceutical industry in promoting development of bone healing with NanoFuse, a bone graft substitute and bone void filler.

Amphix Bio spun out from Northwestern University in Chicago, IL in 2021. The company is developing a new class of supramolecular therapies that instruct cells to initiate regenerative processes and restore function lost from injury, disease, or aging. These therapies contain tens of thousands of biological signals that trigger targeted signaling pathways while forming scaffolds to support tissue growth. Amphix Bio's goal is to use regenerative medicine to increase human healthspans — the length of time that people can live productive, fulfilling lives.

This unique mechanical surgical clamping technology is delivered directly through a fine, minimally invasively, 18 G needle for clamping of blood vessels, ducts, arteries, and veins. The minimally invasive needle delivery results in secure occlusion similar to that of a transfixion suture. SCureClamp with iDOT's anchoring feature secures the implant in place and eliminates slippage. Grasping allows physicians to occlude vessels of varying sizes, types, and wall thickness.

In neuroscience, where so much is yet to be explored, it’s crucial that scientists and researchers can devote their time to discovery. Through a partnership with a team of experts at Amuza, researchers gain access to precise tools that get data right the first time and opens the door to discovery. Amuza is a researcher-focused company. We provide instruments and support to improve productivity and outcomes for life science research and the quality of human life.

Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, we're dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertix's Guardian™ is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.

Stem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans, leading to clinical candidate ART352-L. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.

Anuncia Medical is a neurotherapeutic device company currently solving the large unmet need in cerebrospinal fluid (CSF) management and neurocritical care.

Apollo Endosurgery, Inc. is a medical technology company focused on development of next-generation, less invasive devices to advance therapeutic endoscopy designed to treat a variety of gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, X-Tack TM Endoscopic HeliX Tacking System and the ORBERA® Intragastric Balloon.

Artelon is the leader in dynamic augmentation of tendon and ligament reconstruction. Specifically designed bio-textiles resiliently reinforce the repair of soft tissue: uniquely restoring native motion, resisting the degradation of reconstruction strength, and supporting tendon and ligament regeneration. Dynamic innovations focused on getting people back to motion faster, stronger, and more stable. Learn more by visiting our website or by subscribing to the Artelon YouTube channel.

Artivion is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. Our purpose is to develop simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with diseases of the aorta and deliver breakthrough technologies of unsurpassed quality that have far-reaching impact. Our decades of expertise in treating aortic diseases—coupled with our recent acquisitions and partnerships—have empowered us to offer cardiac and vascular surgeons a suite of aortic-centric solutions such as cryopreserved cardiac and vascular allografts, surgical sealants, prosthetic heart valves, and aortic stents and stent-grafts. Artivion has over 1,250 employees worldwide with sales representation in over 100 countries. The Company has manufacturing facilities located in Atlanta, Georgia, Austin, Texas, and Hechingen, Germany. Additionally, it has sales and distribution offices in various countries throughout Europe, Asia, and South America.

Atreon Orthopedics is a tissue regeneration company powered by breakthrough regenerative technology and renowned scientific expertise. Tendon and ligament injuries affect ten million people yearly, spanning all lifestyles and demographics. Atreon is committed to dramatically improving healing and long-term outcomes for patients encountering these soft-tissue injuries. ROTIUM®, our initial product for rotator cuff repair, is a bioresorbable wick designed as a scaffold to harness and hold biologically active substances at the repair site providing a pro-healing environment that promotes healthy tissue and native tissue regeneration. Recently published human and animal studies and over 10,000 cases have shown a safe and effective solution to improving biology, restoring function, and improving rotator cuff success rates.

Autocam Medical is a precision-machining contract manufacturer of highly engineered implants and instruments for surgical applications. Our product specialties include custom bone screws, bone plates and fixation devices; and perfect-fit complementary, surgical drivers, drill bits, taps and other rotary cutting instruments. We have decades of experience in every aspect of medical machining manufacturing, with specialties in CNC milling, turning, mill/turn and cutter-grinding of all surgical-grade materials, including titanium and other high-performance specialty alloys and plastics. Autocam Medical partners with customers to provide Design for Manufacturability consultation for precision-machined components, involving our engineering team early in the planning stage adds value to the entire process. Our in-depth knowledge of how medical devices work and interact gives customers an added competitive advantage.

Autonomic Technologies is a medical device company that focuses on the development and commercialization of innovative therapies for autonomic disorders, particularly severe headaches.

Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, we’re dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertix’s Guardian™ is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.

AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs. We passionately believe that next-generation lumbar and cervical total disc replacement (TDR) technology will transform the lives of patients on a global scale. Led by an experienced surgeon team utilizing patented viscoelastic polymer technology, AxioMed is developing the next generation of artificial discs. Our Vision: Focusing on restoration of the natural function of the spine, AxioMed will enhance human health through research, innovation, development and service world-wide. AxioMed LLC is a KICVentures company. For all AxioMed jobs visit: http://www.kicventures.com/blog/careers/

Developing seamless neural interfaces.

Axon Therapies is addressing a root cause of heart failure with their frontline therapy by selectively ablating the neural pathway carrying information from the chronically hyperactive sympathetic nervous system (SNS) in order to restore volume balance, stop disease progression and improve symptoms

Becker Orthopedic was founded in 1933 by Otto K. Becker to provide high quality orthotic components and central fabrication services. Today, Becker Orthopedic remains a family business dedicated to quality, service, and innovation in the field of orthotics.

Beta Bionics is a commercial stage medical technology company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWDs) by utilizing advanced adaptive algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared autonomous insulin delivery device in the market and offers the potential to substantially improve overall outcomes across broad populations of PWDs. To learn more, visit www.betabionics.com. For safety information, visit: www.betabionics.com/safety.

Bionex’s mission is to realize the applications of bio-pharmaceutical and life sciences into commercial products and services that benefit human health. Strategically, Bionex engages in two areas of business activities. First, Bionex offers contract R&D services, from early-stage concept development, cGMP clinical supply manufacturing to full-scale commercialization, for bio-pharmaceutical products. Second, Bionex develops and out-licenses its own proprietary formulations, drug delivery technologies, and products related to medical, health food, and skin-care applications. Our expertise is focused on transdermal and transmucosal drug systems. We adopt a science-based, and yet pragmatic and out-of-box approach which often leads to fruitful outcomes, in time- and cost-effective manner. Bionex capabilities are its expertise in formulation science and analytical chemistry, full range of formulation/processing, analytical, and testing capabilities in cGMP facility, and well-connected network of industrial, academic and business consultants and advisors. Many of our in-house innovation R&D projects are funded by National Institute of Health (NIH), National Science Foundation (NSF), state grants and non-for-profit organizations.

BioPoly® was established to provide a treatment option for painful cartilage lesions between the extremes of biological solutions and total joint replacement. Utilizing a patented material that is self-lubricating for improved wear properties (via a biological enhancement with Hyaluronic Acid) the BioPoly® RS devices are uniquely designed to replace only the damaged cartilage. Therefore, patients can quickly recover and return to pain-free, active lifestyles. BioPoly® RS devices are currently available for femoral condyle, trochlear facets, trochlear groove, patella, and humeral head applications. Patients out to >10 years have experienced a significant reduction in pain and have shown improved quality of life. Additional orthopedic applications are currently in development. BioPoly® serves healthcare professionals and their patients throughout the world from our headquarters in Fort Wayne, Indiana, USA.

Biostage is a biotechnology company that focuses on developing organ replacement therapies using cellular scaffolds and tissue engineering.

BioSurfaces, based in Ashland, Massachusetts, is a life science company with deep leadership and a diverse team of specialists. The company's proprietary electrospinning technology known as Bio-Spun™ creates product solutions by engineering biology with synthetic cellular matrices for applications ranging from IVRT and delivery of bio-active therapeutics to medical devices and consumer health products. These materials can be made to form a variety of unusual and difficult-to-manufacture shapes while also demonstrating improved biocompatibility over other textile-based materials. The BioSurfaces manufacturing process also allows the incorporation of drugs or other bioactive agents directly into the nanofibers for localized release. BioSurfaces' technology is validated by leading organizations in pharmaceuticals, medical devices, life sciences, and consumer products.

BiVACOR is a medical technology company that specializes in developing advanced artificial heart solutions.

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

Cadence Neuroscience is developing a fundamentally new approach to neuromodulation, starting with a therapy to treate severe epilepsy.

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an oral therapeutic designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular (CV) conditions. Cadrenal strives to improve outcomes and reduce adverse events for these patients such as strokes, heart attacks, bleeds, and deaths. These patients also lack approved chronic anticoagulation options besides warfarin, well-known for its serious side effects and frequent drug-drug interactions, resulting in complicated treatment management. Cadrenal’s drug candidate, tecarfarin, is a new VKA anticoagulant with extensive clinical data showing it is potentially superior and safer than warfarin, resulting in fewer adverse events. Tecarfarin is metabolized via a different pathway than warfarin and data demonstrate that its efficacy is unaffected by common drug-drug interactions or kidney impairment, which are common in these patients. Phase 2/3 clinical trials show that tecarfarin may offer more stability and time in therapeutic range (TTR) that inversely correlates with major events. Tecarfarin received an orphan drug designation for advanced heart failure patients with left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (ESKD) patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal clinical trials with LVAD patients along with clinical and commercial partnership opportunities to advance tecarfarin. The company’s plans also include studying patients with mechanical heart valves who experience anticoagulation difficulties because of genetic warfarin resistance, polypharmacy, or kidney impairment. For more information, please visit: www.cadrenal.com.

Cagent Vascular (Wayne, PA) has developed and commercialized its novel angioplasty balloon with Serration Technology to treat blocked arteries in the leg or Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). The Serranator PTA Serration Balloon Catheter is the first and only angioplasty balloon with serration technology

Caldera Medical is a medical device company solely focused on women's health with a commitment to our mission of "Improving the Quality of Life for Women!" We develop, build and market best in class surgical products for the treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse. Working closely with surgeons to help those here at home, as well as women around the world, through our humanitarian programs to give them the access to the education and treatment they deserve. Mission - To Improve the Quality of Life for Women Vision - To be the Global Leader in Women's Pelvic Health Values "C4"​ - Care / Collaborate / Challenge / Create

Innovative spine and medical technology company Camber Spine is dedicated to creating surgeon-designed solutions in MIS and minimally disruptive access for the treatment of complex spinal pathology. Incorporating state-of-the-art manufacturing, 3-D printing, and an acute sensitivity to patient anatomy, we are making quantum leaps in the spinal fusion market. Our patented OLIF system and procedure – with its less complicated, simpler approach to treating complex spinal pathologies – is poised to change the way spine care is delivered. Camber Spine now has 20 products with 510(k) clearances and over 28 active or issued patents, including two award-winning, highly innovative and IP protected device platforms that support faster spinal fusion and recovery: ENZA® (MIS Integrated Interbody) spinal fusion implants; and SPIRA® OA (Open Architecture 3D printed) spinal fusion and orthopedic implants. Our 27,000 sq. ft. state-of-the-art facility just outside Philadelphia features meeting facilities, office spaces, a mechanical test lab with full prototype shop and an expanded double cadaver lab.

At Capstan Medical, we’re driven by an unwavering commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, we’ve pioneered a patient-optimized approach to repair and replace heart valves.

Cardiovascular Systems, Inc. (CSI) is committed to providing innovative solutions for the revascularization of patients with complex coronary and peripheral artery disease (PAD). Our primary focus is helping physicians conquer even the most difficult disease states, including the challenge of arterial calcium for the millions who suffer from PAD and Complex PCI. CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe, effective, economical medical devices that improve patient outcomes. We are equally committed to creating an invigorating work environment for people who align with our Core Values of accountability, integrity, excellence, courage, velocity, and community. When each of our employees lives our Core Values, we're doing everything we can to achieve our mission: Saving Limbs. Saving Lives. Every Day. It is the policy of CSI to provide equal employment opportunity (EEO) to all persons regardless of age, color, national origin, citizenship status, physical or mental disability, race, religion, creed, gender, sex, sexual orientation, gender identity and/or expression, genetic information, marital status, status with regard to public assistance, veteran status, or any other characteristic protected by federal, state or local law. In addition, CSI will provide reasonable accommodations for qualified individuals with disabilities. For more information, visit www.CSI360.com or connect with us on Twitter and Facebook. Read important safety information (https://csi360.com/indications-statements-important-safety-and-risk-information/).

Alta Biomaterials is a biomedical company that specializes in design and development of proprietary coating and surface modification technologies for medical device OEMs.

CeloNova BioSciences is now ALTA Biomaterials! In Jan 2023, CeloNova BioSciences has become Alta Biomaterials! Alta Biomaterials is an expert design and development partner to medical device OEMs looking for proprietary coating and surface modification technologies that enhance biocompatibility and drug delivery while providing anti-inflammatory, thromboresistance and pro-healing properties.

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through design, uncompromising quality standards, and the most technologically advanced manufacturing platforms.

CereVasc, Inc. is a clinical-stage, medical device company developing novel treatments for neurological diseases. The company is focused on developing the eShunt™ System for the treatment of patients with hydrocephalus. CereVasc aims to improve patient outcomes and redefine the treatment of communicating hydrocephalus through its innovative medical devices.

CivaTech Oncology® designs innovative products that bring meaningful improvements to low dose rate brachytherapy. The CivaString® and CivaSheet™ can substantially reduce procedure time, provide homogeneous dose distribution and minimize trauma. Customizable CivaTech products ensure that radiation oncologists can deliver individualized, targeted therapy to treat cancer. http://www.civatechoncology.com/

Perfecting the Sense of Sight. Clerio Vision is developing a revolutionary product platform for the global ophthalmic market, based on technology licensed from the University of Rochester. The company is in the process of developing and commercializing a portfolio of next generation products in contact lenses, myopia control and cataract surgery. The team is composed of serial entrepreneurs with multiple exits as well as ophthalmic industry veterans who pioneered a number of new ophthalmic technology categories. The products are currently in clinical development.

Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

CompactCath is a medical device company committed to improving the quality of life for self-catheterizing patients, their families, and healthcare providers. Designed and founded at Stanford University by a team of physicians, engineers, and catheter users, we are driven by a goal to design medical devices that enable those with chronic conditions to lead active, thriving, independent lives. CompactCath, our flagship intermittent urinary catheter, is a revolutionary pre-lubricated, non-touch catheter for users looking for a compact, discreet, and easy to use solution that fits seamlessly in their lives. CompactCath is FDA cleared in the US and CE approved in Europe. For more information, visit our website: www.compactcath.com and watch our video: https://www.youtube.com/watch?v=k8cjjgfGhAY

ConKay Medical Systems is an early-stage medical device company advancing unique solutions to treat valvular regurgitation in patients with progressive heart failure. Valvular regurgitation is when your valves do not close properly allowing blood to flow backwards in your heart causing shortness of breath, chest pain, and sometimes death. There are over 100 million people currently affected globally with valvular disease and an additional 5M Americans are diagnosed each year. ConKay's annular repair technology is designed to treat the main cause of functional regurgitation leaving the healthy leaflets intact to perform the way it was intended. We are currently focused on the Tricuspid valve. Message us for more information!

Our Mission Patients vary in more ways than gender, race, and size. At Conformis, we believe that optimizing implant fit and performance requires a personalized approach. Our mission is to provide best-in-class, personalized joint replacement systems and instrumentation that offer unique advantages over traditional orthopedic implants. We pioneered full personalization with a simple idea: make the implant fit the patient rather than forcing the patient to fit the implant. Our fully personalized implants are individually sized and shaped to fit to each patient’s unique anatomy, providing precise anatomic fit and preserving healthy tissue. Our disposable, patient-specific cutting and placement guides also eliminate many of the tools required for traditional orthopedic surgery and simplify surgical technique. By combining our personalized implants with our unique instrumentation, a surgeon is able to provide a solution that preserves more of a patient’s joint and minimizes surgical trauma. Our Company Conformis, Inc. is a publicly traded medical device company based in Massachusetts. It was founded in 2004 to provide dramatic advancements in patient care by utilizing imaging technology to create personalized, patient-specific implants and instrumentation.

CoraVie Medical's implantable, continuous blood pressure monitor informs treatment decisions to improve lives. The end to end solution improves patient compliance to monitoring and improves blood pressure reliability and actionability. By monitoring trends over day and night, CoraVie enables timely notification of changing health status.

Cordis is a medical devices company that specializes in cardiology equipment and healthcare technology.

Johnson & Johnson Innovation JLABS @ TMC, Houston. With a lead investment from the UK-based Wellcome Trust, a premier international medical foundation, CorInnova is developing a non-blood contacting cardiac assist device. CorInnova's device is a transformative biventricular device to treat acute heart failure. The technology will create a new paradigm for treatment. The device is designed to eliminate adverse events associated with existing cardiac assist technologies, and to expand eligible patients. The device may reverse the progression of HF, a blockbuster application. The device deploys minimally invasively into the pericardial sac in under 30 seconds, and has shown the ability to increase cardiac output by up to 50%. Addressable markets are up to $10 billion.

Corvia Medical, Inc. is revolutionizing the treatment of heart failure with a novel transcatheter structural heart device. Founded in 2009 and headquartered in Tewksbury, MA, Corvia Medical is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. The Corvia® Atrial Shunt is the world’s first transcatheter device approved by the European Union to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction. Privately held, the company is backed by Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures, Edward Lifesciences and an undisclosed strategic investor. In the United States, the Corvia Atrial Shunt System is an investigational device and not available for commercial distribution or sale.

Cryosa is a clinical stage company developing a treatment for moderate to severe Obstructive Sleep Apnea (OSA). We believe that mask-free, hose-free, implant-free treatment is possible. Everyone is free to sleep, free to rest and free to live brighter days.

CTM is dedicated to developing surgical implants to help physicians treat post-operative biologic issues that are beyond their control.

Curiteva is a privately held technology and manufacturing company dedicated to advancing spine surgery and improving clinical outcomes by partnering with providers and suppliers to deliver innovative and intuitive implant systems to the market. Our business is founded on a commitment to building world-class manufacturing, accelerating research and development, maintaining lean operational discipline, and delivering novel technology to meet the evolving needs of our customers and the patients they serve.

CurvaFix is developing implantable products to improve fracture repair in curved bones. The company is focusing on Fragility Fractures of the Pelvis (FFP) and high-impact pelvic fractures. The CurvaFix® IM Implant is the only intramedullary device capable of following the natural bone shape and filling the space within curved bones such as the pelvis.

CVRx is a commercial stage, public (NASDAQ: CVRX) medical devices company located in Minneapolis, Minnesota. The company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim™ triggers carotid baroreceptors - the body's own natural blood flow regulation system - which signals the brain to regulate cardiovascular function. Patient Stories on CVRx: The accounts and quotes of patients are genuine and documented. These stories represent a unique individual experience and does not provide any indication, guide, warranty or guarantee as to the response other people may have to CVRx technologies. Barostim is a prescriptive device. For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/

CystoSure is a novel device specifically designed for safe, efficient and standardized visualization of the female bladder and ureteral openings. Building off of a traditional Foley catheter design, CystoSure introduces a whole new means of safely and comfortably evaluating the female bladder.

Duke University spin-out, Deep Blue Medical Advances has developed a novel hernia mesh to address the unacceptably high rate of hernia occurrence and recurrence. Millions of hernia surgeries are done globally with billions of dollars in clinical cost. Our surgeon-invented T-Line® Hernia Mesh with integral suture-like extensions is designed to eliminate a key point of failure for conventional mesh fixation - the mesh, suture, tissue interface - and to provide superior anchor strength. In addition, several additional products are in development, including an anchor clip for even faster, easier implantation; a biosynthetic version of the T-Line Hernia Mesh; and a coated composite version of the T-Line Mesh. Deep Blue products enhance hernia surgery with a potentially significant impact on the $1.1B global hernia device market. Due to its simple yet revolutionary design, the T-Line® Hernia Mesh has the potential to reduce hernia occurrence and recurrence by preventing or reducing mesh fixation failure.

Delpor is a clinical stage life sciences company that utilizes innovative drug-delivery technologies in order to develop once-yearly therapies for chronic conditions. The Company’s lead product is a 6-12-month formulation of Risperidone (drug/device combination product) for the treatment of schizophrenia. Delpor is also pursuing 6-12 month formulations of other drugs targeting CNS conditions including Neuromuscular Diseases, Neurodegenerative Diseases, Addiction, and other disorders.

DiFusion Technologies, Inc. is an industry leader in advanced biomaterials for surgical implants. DiFusion Technologies is revolutionizing the field of implant technology by developing innovative solutions that reduce the foreign body response from the patient's immune system, thereby promoting early healing, reducing complications, and improving patient outcomes. The company's proprietary manufacturing process produces implants that decrease chronic inflammation currently associated with traditional biomaterials. Redefining the landscape of healthcare technology, our surgical implants cater to the precise needs of orthopedic surgeons, neurosurgeons, spine surgeons, and medical device distributors. By setting unprecedented standards in the industry, we're not just creating products - we're shaping the future of surgical care. Discover more about our groundbreaking surgical devices at difusiontech.com.

Dimension Inx is the architect of regenerative microenvironments. Our materials give the body a blueprint to heal itself. We take a materials-centric approach to solving patient needs. By creating structures that emulate the body's microenvironment, we elicit an immediate regenerative response. We design for biofunctionality and manufacturability. Our platform is highly adaptable and not limited to any single material. Our collaborative studio approach allows us to co-create a lasting advantage by partnering with leading product and R&D organizations. Contact us to accelerate the development of new regenerative solutions today.

Engineering and Design of Implantable Medical Devices We are the industry leader in Engineering and Design of implantable medical devices and have helped many companies through the product development and regulatory approval process. ECHOBIO LLC has over 18 years of experience with medical devices including self-expanding and balloon expandable stents, stent grafts, heart valves and others, as well as a strong background in implantable materials (metals, polymers, ceramics and biomaterials). This experience provides a solid foundation for using FEA and improves our simulation of devices and surgical procedures. We participate on international standards committees and pioneer innovative materials research to develop better engineering methods for making safe and reliable implantable medical devices. Our goal is to put our engineering and medical product expertise to work for customers and partners, helping them to move quickly and confidently to market with safe and effective products. From concept through design, development and regulatory approval, ECHOBIO LLC can help you create better products.

EchoPixel is building a new world of patient care with its interactive, 3D medical visualization software. The True 3D system allows medical professionals to interact with patient-specific organs and tissue in an open 3D space emanating from a display, enabling doctors to immediately identify, evaluate, and dissect clinically significant structures. In diagnostic, surgical planning and image guided treatment applications, EchoPixel is a privately held, venture backed company located in Santa Clara, CA.

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. For more information, visit www.bostonscientific.com and connect with us on X, Instagram, and Facebook. At Boston Scientific, you will find purpose, a place to grow and opportunities to cultivate your passions. To search and apply for open positions, visit https://bostonscientific.eightfold.ai/careers. You may also review our social media guidelines at http://www.bostonscientific.com/social.

Elixir Medical is committed to transforming care of patients with heart and vascular disease through innovation. Since 2005, the company has continually sought to improve the treatment of vascular disease with: - Drug-eluting coronary stent systems (DES) - Fully resorbable drug-eluting scaffold systems (BRS) - Drug-eluting coronary bioadaptor systems Its latest innovation — the DynamX™ Coronary Bioadaptor System — is designed to be a significant advancement beyond drug-eluting stents (DES). Elixir Medical’s innovations are designed to make a meaningful change in patients’ lives. The company does not simply want to engineer a better medical device. Saving lives and helping patients enjoy their daily life is what drives us every day.

At Elutia we’re pioneering the future of patient care. Our proprietary drug-eluting biomaterial platforms stand at the forefront of medical innovation.

Embody, Inc. is a commercial-stage company pioneering the next generation in collagen-based tendon and ligament healing for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.

Empirical Spine, Inc., is focused on developing disruptive solutions for the surgical treatment of spinal disorders, in order to deliver superior clinical outcomes while lowering overall healthcare costs. We are building a new standard in spine surgery that works in parallel with the natural structures of the spine to restore functionality and optimize quality of life by creating a new category called Dynamic Sagittal TetherTM (DST). For patients with mobile degenerative spondylolisthesis, LimiFlexTM is the first and only Dynamic Sagittal Tether that restores the natural motion and stability required after a decompression by augmenting the posterior tension band, creating elastic resistance to flexion and maintaining lordosis, and offers the potential for significant reduction in cost, invasiveness, and sequelae compared to spinal fusion. The U.S. pivotal trial on our breakthrough LimiFlex Dynamic Sagittal Tether is fully enrolled and nearing its two-year endpoint. In summer 2022, we expect to submit results from this trial to the FDA for PMA approval. Follow our LinkedIn page for company news and updates. For more information about LimiFlex Dynamic Sagittal Tether visit the following website: https://www.limiflex.com/. Caution: The LimiFlex DST is an investigational device in the U.S. and is limited by law to investigational use.

ENCOLL CORP. is a medical devices company based out of 4576 ENTERPRISE STREET, FREMONT, California, United States.

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. We have a therapeutic portfolio designed to treat diseases which currently have clinically relevant unmet needs. Our existing products can treat a wide spectrum of vascular disease through abdominal aortic aneurysms to lower limb peripheral vascular disease. We obtain excellent clinical outcomes through meticulous attention to product design, manufacturing, and training, all backed by industry-leading clinical evidence. With a robust pipeline of disruptive technology, our vision is to provide physicians with the best device for each patient; because when it comes to ensuring patient well-being, we are never satisfied with the status quo.

In many medical settings, devices are commonly used to help doctors treat patients. For example, stents are often used to open blocked arteries, repair torn vessels, and even to keep nasal passages from swelling shut after surgery. Unfortunately these devices fail often resulting in additional surgeries and often replacements of the original device. Endomimetics has developed a BioNanomatrix that can be used to coat these devices and mimic human tissue which minimizes the need for additional surgeries, improves the longevity of the device, reduces complications associated with having foreign items implanted in your body. Applications Our endothelium mimicking nitric oxide releasing BioNanomatrix, initially developed for coronary and peripheral stents, is being assessed for several novel applications including: Stents to help with heart disease Stents and blood flow diverters to help with brain aneurysms Fistula implantation for dialysis patients Intranasal implants for chronic sinusitis sufferers

Enovis is a data analytics company that provides technology solutions for business intelligence and information management.

Envoy Medical (Nasdaq: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

EpiBone is a revolutionary bone reconstruction company that allows patients to "grow their own bone". EpiBone's pioneering technology utilizes a scan of the patient's bone defect and the patient's own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.

Our mission is to improve the lives of stroke victims suffering from difficulty with movement and coordination. Standard rehabilitation can help a patient recover some muscle function. However, mild electrical brain stimulation, when administered in conjunction with muscle training, has been shown in published research studies to significantly improve a patient's ability to move, resulting in often dramatic improvements to quality of life, when compared to muscle training alone. The EPIC Stimulator is a tiny leadless device that provides short low-energy electric pulses directly to the cortex. The implant procedure is very simple (~15 min). The EPIC contains no battery and is externally powered through a comfortable cap. The cap is only worn by the patient during muscle training (about an hour a day for 3 months). After all rehab is complete, the EPIC devices can be easily removed if desired. In addition to mild brain stimulation, the EPIC allows the recording of a patient's EEG, which is streamed to a handheld device and then to the cloud. This allows neurological changes in the brain to be tracked and quantified. Note, the EPIC is not approved by the FDA for human use. It is only for investigational use as part of a clinical trial.

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Exactech is a global medical technology company that empowers orthopaedic surgeons with innovative implants, surgical instruments and the Active Intelligence® (AI) ecosystem of smart technologies to give patients EXACTLY what they need to regain mobility. Visit www.exac.com for more information. Exactech will never ask you to conduct an interview via text message. We value your privacy and do not ask applicants for financial information or ask applicants to make any purchases. If you believe that you have been contacted by a cybercriminal, please contact your local police department.

Fennec Pharmaceuticals is a biotechnology company focused on improving the lives of children with cancer by addressing chemotherapy-induced hearing loss.

Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity in many patients, leaving many survivors of childhood cancer with permanent and irreversible hearing loss. Permanent hearing loss, even minimal, acquired at a young age has a devastating impact on development, education, and socialization and a lifelong negative impact on Quality of Life. There are no currently approved treatments for the prevention of platinum-induced hearing loss. At Fennec Pharmaceuticals, we are dedicated to the development of our investigational agent, PEDMARK™, for the prevention of ototoxicity in children, and we hope that this will enable more children to retain their hearing. In honor of our namesake, the fennec fox, we strive to embody adaptability and resourcefulness in everything we do. Please see www.fennecpharma.com for more information.

For ordering information, please contact: 3M+KCI at +1-800-275-4524, KCI Express® https://mykci.com/kci-express, or Your local 3M+KCI Sales representative ________________________ Managing ostomy complications and intestinal fistulas is a challenge. A high output ostomy stoma or enteric fistula can produce two to seven liters of effluent per day which can cause edema, wound formation, complications and infections. To improve the management of patients with enteric fistulas and high output ostomy stomas we developed the Wound Crown®, Fistula Funnel® and Isolator Strip®. These barrier devices have been used effectively to compress the surface of the body around enterocutaneous fistulas, enteroatmospheric fistulas, ostomy stomas, and wound drains with moderate to high output levels to seal and protect the perimeter skin from effluent and reduce edema.

Our Vision: To revolutionize the structural heart market with new material, design and manufacturing technology expanding patient access, improving product performance and significantly reducing costs.

Freudenberg Medical is a global partner for the design, development and manufacture of medical devices, components, and minimally invasive product solutions. Our comprehensive technical capabilities range from the design and manufacture of minimally invasive, catheter, and handheld technology to the development and production of medical components utilizing advanced materials and processes. We are an industry leader in the manufacture of high precision silicone and thermoplastic components and tubing as well as metal hypotubes and coating technology. Freudenberg Medical is part of the Freudenberg Group, a global technology group. As an organization, we ensure that every project is supported by our unmatched range of global resources, financial stability, and the flexibility to optimize for business performance. www.FreudenbergMedical.com Explore the possibilities with Freudenberg Medical, please call 877-308-0558 or email info@freudenbergmedical.com

FUSE Medical is an emerging medical device company committed to the advancement of anatomical motion, preservation, and restoration by offering Surgeons a fully comprehensive implant product selection for use in areas of: Spine Total Joint Reconstruction Sports Medicine Upper Extremity Lower Extremity Biologics Regenerative Medicine HEADQUARTERS Richardson, Texas - 20-minute drive from DFW airport PRODUCT LINES Spine Fusion Total Joint Reconstruction Sports Medicine Line External Fixation Options Comprehensive Foot Plating Systems Compression Stapling Systems Hammertoe Full Biologics Portfolio Rotium Tendon to Bone Bioresorbable Wick Phoenix Wound Care Synthetic Matrix BMAC PRP STERILE PACKAGED SYSTEMS Hammertoe Distal Radius Distal Fibula Lapidus MTP Clavicle Plating Cannulated Screws DISTRIBUTOR BENEFITS Comprehensive portfolio Robust product pipeline National distributors for thousands of products Transparency Grow with us!

GENESEARCH, INC is a biotechnology company that specializes in embryonic manipulation techniques for biomedical research purposes.

At Glucotrack, we are pioneers in diabetes technology, dedicated to transforming the way diabetes is managed. Our mission is to develop innovative, long-term solutions that prioritize accuracy and ease of use. With a commitment to reducing the daily burden of diabetes management, we create cutting-edge technologies designed to enhance the lives of those we serve. Join us in our journey towards a future where managing diabetes is simpler, more effective, and empowering.

March 20,2023 CalciMedica Inc. (CalciMedica) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the closing of its previously announced merger with Graybug Vision, Inc. CalciMedica’s stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol “CALC”. Immediately prior to the closing of the merger, CalciMedica completed the previously announced private placement of $10.3 million. With the closing of the merger, CalciMedica has approximately $34 million in cash and cash equivalents, which is expected to provide the company a cash runway into the second half of 2024 and fund the advancement of Auxora through clinical milestones in 2023,

HAPPE is an emerging leader of next generation orthopaedic and spinal implants enabled by the HAPPE™ (HydroxyApatite Porous PolyEtheretherketone) platform. The HAPPE material platform offers interconnected, cancellous porosity with exposed hydroxyapatite on pore surfaces to enable robust bone in-growth and on-growth confirmed in preclinical testing.

HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases.

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. We sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including GE Healthcare, Thermo Fisher Scientific Inc., and VWR. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, and Spain and sales facilities in France and Canada.

Healionics is addressing the critical need for safer, more reliable means of bloodstream access to perform dialysis in patients with kidney failure. Our STARgraft vascular graft (synthetic blood vessel) is designed to resist the problems of occlusion and infection suffered by current devices. We also have an exciting product pipeline based on our platform STAR® biomaterial, which has a unique ability to prevent two serious problems that affect all implantable devices: scarring and infection. The company is currently conducting human studies of STARgraft and has 36 patents issued or pending.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS). PoNS™, short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS Therapy™. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait. PoNS is authorized in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS is authorized in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. PoNS is authorized in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.

Hydromer® is a leading global surface modification and coatings solutions provider. As a trusted partner to companies worldwide, our solutions add value to our clients’ products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients’ needs. Hydromer collaborates extensively with clients to deliver superior, customized polymer-based solutions. We create or modify coating formulations that adhere to a multitude of substrates and match the unique requirements and geometries of any device. We are a leader in developing coating formulas and processes that meet a market-driven need for greener, more sustainable solutions. We offer custom industrial and medical device coatings, contract coating services, customized coating equipment, contract manufacturing, and turnkey operations backed by outstanding teams of research and development, customer service, and tech support. Hydromer® has been a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices for over 40 years. As a trusted partner to large and small companies worldwide, our solutions add value to our clients’ products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients’ needs. We are a GMP/ISO 13485 and ISO 9001 production facility located in Concord, North Carolina.

IGENOMIX USA is a biotechnology company that specializes in genetic testing services for reproductive health and fertility.

Implant Surfaces offers surface solutions for spinal, orthopedic, cardiovascular, and neurovascular device and instrument applications. Our advanced nano-engineered coatings and surface treatments enable a wide range of product enhancements including biocompatibility, optimum tissue integration, biofilm resistance, wear and corrosion resistance, reduced friction, hydrophilicity, hydrophobicity, anti-glare surface, aesthetic and color-coding, and desired electrical properties. Our surface modification capabilities include physical vapor deposition (PVD), Atomic Layer Deposition (ALD), Chemical Vapor Deposition (CVD), as well as our proprietary Atomic Plasma Deposition (APD™), Nano Plasma Deposition (NPD™), and Molecular Plasma Deposition (MPD™) processes.

Impulse Dynamics is a fast-growing medical device company that has pioneered a new form of therapy for heart failure called Cardiac Contractility Modulation, or CCM. The Optimizer Smart is the first implantable device for the treatment of chronic heart failure in patients with normal QRS durations.

Innervace is a regenerative therapy company developing technology that acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury. Our lead program mimics the lost migrostriatal pathway in patients with Parkinson's disease (PD).

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries and regions. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. Santen Pharmaceutical Official Social Media Global Terms of Use​ https://www.santen.com/en/legal/

InnovHeart, with locations in Milan, Italy, and Boston, Massachusetts, develops transcatheter mitral valve replacement (TMVR) systems to treat patients suffering from mitral valve disease. The company is currently in clinical trials testing its novel TMVR Saturn Prosthesis, designed to be consistent with the anatomy of the mitral valve. Saturn is a low-profile prosthetic designed for both Trans-apical and Trans-septal delivery. Our company mission is to bring patients a novel therapeutic system suitable to replace incompetent Mitral Valves based on a safe, effective, and easy-to-use transcatheter technology. InnovHeart is committed to pursuing this goal with the highest level of quality.

inQB8 is a med-tech incubator founded in 2018 to develop novel, device-based solutions for the biggest cardiovascular challenges and create successful start-ups that can bring those solutions to the patients that need them most.

To make bold and positive change in the biomedical and technology markets. An innovation hub, we relentlessly pursue ideas and inventions that result in superior products, processes, and design. This relentless pursuit drives us every day to bring ideas to market that improve lives and give back to the communities in which we operate.

XENT was acquired by MDT on 5/13/2022 Intersect ENT (Nasdaq:XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients.

InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most prevalent underlying causes of these symptoms. InterVene plans to change that. InterVene was originally a product of the Stanford Biodesign Fellowship and is a former Company In Residence at the Fogarty Institute for Innovation. InterVene's offices are now located in South San Francisco near SFO airport.

Adjacent to a lumbar discectomy, the Barricaid® device is designed to close large defects in the annulus, which often lead to disc reherniation and/or disc collapse. Barricaid is a permanent implant with two components - a titanium bone anchor and a flexible polymer barrier. The barrier is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position. The Barricaid has been studied in a definitive – level 1B evidence - randomized superiority trial with over 550 patients enrolled (clinicaltrials.gov NCT01283438). The study focuses on patient at highest risk of reherniation and reoperation, enrolling only those patients with large defects (width >5 mm). The co-primary endpoints of reherniation and an 8-point composite of safety and effectiveness are evaluated at 2 years, with a parallel cost effectiveness analysis. Treated patients were found superior on both endpoints, with significantly lower rates of symptomatic recurrences (12% vs. 25%, p<0.001), index-level reoperations (9% vs. 16%, p=0.01), and device or procedure related serious adverse events (SAEs) (7% vs. 17%, p=0.001). Through two years, a total of 29 reoperations were performed in Barricaid subjects in comparison to 61 procedures in Controls. Study results are published in The Spine Journal, May 2018. Barricaid is FDA-Approved For full risk/benefit, see: www.barricaid.com/instructions-for-use

iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, iTOL-100, we are advancing a pipeline of programs using both allogenic pancreatic islets and stem-cells that have the potential to cure diseases. Our lead program, iTOL-101 is being developed for Type 1 Diabetes and in a preclinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our follow-on candidate, iTOL-102 is leveraging significant advancements in stem cells, which allows a potentially inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-301 as a potential regenerative protein and cell therapy that leverages stem cell sources to produce proteins or hormones in the body in conditions of high unmet need.

JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR. JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.

Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. KALA BIO is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye. KALA BIO’s biologics-based investigational therapies utilize KALA BIO’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA BIO’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA BIO is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA BIO, please visit www.kalarx.com.

Corneal Surgery Devices

LambdaVision is developing the first protein-based artificial retina to restore meaningful vision for patients who are blind or have lost significant sight.

Genomic Prediction provides advanced genomic tests which improve IVF health outcomes. Genomic Prediction Inc. (GP) was incorporated in Delaware, May 1, 2017. The research insights which led to the creation of GP stretch back much further. Research and data exchange agreements to develop molecular methodology, signed with some of the largest biotechnology vendors in the world, were ongoing as early as 2015. In the decade prior, the founders’ work in embryology, detection of chromosomal abnormality, computational genomics, algorithms, and polygenic architecture led to GP’s superior and innovative methodology for the genetic testing of human embryos. GP’s products incorporate fundamental improvements on existing methods. GP offers IVF parents a cost-effective means to evaluate genetic risk due to chromosomal abnormality (ploidy), single-gene mutations, and polygenic diseases. Accurate understanding of the genomic architecture of human disease requires larger training datasets, greater accuracy, and a more rigorous, empirical basis of computational modeling (machine learning) than implemented in the past with simpler technologies and simpler computational methods. GP represents the next step in embryo genetic testing, combining dense, genome-wide genotyping methods with sophisticated validation-focused modeling, suitable for the information age.

The Lifewave solution will establish a new standard-of-care for the guided-care of heart failure patients. Our solution consists of a digital AI-powered platform, and differentiated by a medical radar lung sensor that is non-invasive, simple-to-use, low cost, and provides a direct and absolute measurement of lung fluid for guiding care.

LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis’ lead preclinical program is focused on liver regeneration for patients with end stage liver disease. Other therapeutic targets for organ regeneration include the thymus, pancreas, and kidney. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania.

Marizyme, Inc. is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes.

Mass Eye and Ear in Boston is a Harvard teaching hospital dedicated to eye (ophthalmology) and ear, nose, throat, head and neck (ENT) care and research.

Matexcel is a service provider in materials science, with years of commitment to supply better polymers, nanoparticles and other materials for worldwide customers from both academia and industry. They offer a full range of materials covering polymers, metals, ceramics and natural materials, in addition to professional consultation service in manufacturing and characterization. Our experienced team of scientists have mastered a wide spectrum of technologies to solve interdisciplinary tasks such as custom synthesizing and developing polymeric and nano-bio applications. They are a customer-oriented company aiming to deliver product and service to the global pharmaceutical and nano-biotechnology markets.

MedSpark is a medical technology company that specializes in developing innovative medical devices.

Medtronic plc is an Irish medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Dublin, Ireland. Medtronic operates in more than 140 countries and employs over 90,000 people worldwide. The company is the world's largest standalone medical technology development company.

Melodi Health offers novel technologies that improve patient outcomes for women undergoing breast surgery. Melodi Health manufactures the Melodi Matrix, designed to support the soft tissue space around a prosthetic device while delivering antibiotics to the surrounding tissue. The Melodi Matrix is currently an investigational device being studied in a prospective, multi-center, randomized, controlled clinical trial in breast reconstruction.

As a global healthcare company, we understand customer needs and innovate and deliver medical solutions that transform patient care. Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 300 individuals. Merit employs approximately 6,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore.

Developer of bio-engineered surgical implants designed to facilitate new tissue growth and also aid in connective tissue repair. The company's implants specialize in viable alternatives to conventional ACL reconstruction for patients who have sustained any kind of leg injury, enabling surgeons to perform surgery to restore normal anatomy and function of the knee.

Mission: Manufacturing excellence through a commitment to quality, integrity, and servant leadership. Founded in 1988, Micropulse is a privately held, precision manufacturer focused on earning long-term partnerships with leading orthopedic companies built on trust, honesty, and open communication. Micropulse manufactures implants, instruments, cases and trays, and provides packaging and inventory management for orthopedic OEMs. Northeast Indiana has been home for the company since its inception. Customers can trust Micropulse to be a responsible, accountable, and committed partner backed by technology, capability, and scalability.

Since 1996, Minnetronix Medical has accelerated medical device breakthroughs as a design, development and manufacturing partner to leading device companies around the world. Today, through life-cycle efficiency, opportunity realization, and increased utility, the organization is creating value in key technology segments, including RF energy, fluid and gas management, optical systems, and stimulation and active wearables. From design and manufacturing services to whole product solutions, Minnetronix brings expansive industry insight and intentional technical acumen, delivering better medical devices to market, faster. Minnetronix is based in St. Paul, Minnesota. ​

What we know: - Currently, 106,000 people in the U.S. are on the waitlist for a life-saving organ transplant. - 60% of patients on the waitlist will not receive the organ they need. - 17 people in the U.S. die each day due to the lack of available organs. What we're doing: Miromatrix Medical was founded with the mission to eliminate the transplant waitlist. Headquartered in Eden Prairie, Minnesota, we bioengineer organs through our patented perfusion decellularization and recellularization technology. We take what nature designed -- a fully functioning liver or kidney -- and with our patented technology, remove all of the cells from discarded pig organs. What's left is a ‘scaffold'; all of the organ's natural design and architecture remains. Then, from the inside out, we seed new, living human cells back into the organ -- ultimately creating completely functional, transplantable organs with the potential to save thousands of lives every year.

The MDI Biological Laboratory, located in Bar Harbor, Maine, is an independent, non-profit biomedical research institution focused on increasing healthy lifespan by slowing the aging process and enhancing our natural ability to repair and regenerate tissues damaged by injury or disease. We develop solutions to complex human and environmental health problems through research and education, and our innovative and collaborative approach encourages shared learning and is based on the recognition that all life is interconnected.

Implantable Shock Absorbers for Knee OA

Nalu Medical, Inc. is a privately held commercial medical device company based in Carlsbad, California. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The system is highly capable and easily upgradeable, providing a menu of therapy options.

Nanofuse is a regenerative therapeutic that has the properties of replacing or "regenerating" human bone cells to form normal bone. NanoFUSE Biologics products contain the only bioactive glass that is FDA-Cleared to be combined with demineralized bone matrix (DBM). The regenerative efficacy comes from the osteoinductivity of the DBM component plus the osteopromotivity of the bioactive glass. Bioactive glass has been clinically proven for over 30 years but only until now has NanoFUSE Biologics used bioactive glass to create a revolutionary and patented regenerative therapeutic.

NanoHive Medical (formerly HD LifeSciences) created the proprietary, biomimetic Soft Titanium technology, which clearly distinguishes their products in the $1.9B spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provides surgeons and their patients with the ideal features that lead to consistently strong fusion constructs and efficacious clinical experiences.

NANOVIS is a rapidly growing nanotechnology surface company. Our scientists use a broad portfolio of advanced nanotechnologies designed to improve spine, orthopedic, and dental surgical outcomes. nanoVIS Ti ™ Surface Technology received FDA nanotechnology designation and is cleared on commercially pure titanium and titanium alloy implants.

Natus Medical Incorporated (Natus) offers medical equipment, software, supplies and services for the diagnosis, monitoring, and treatment of impairments and disorders effecting the brain, neural pathways, and eight sensory nervous systems. Our comprehensive product portfolio represents a heritage of innovation and leadership. Natus brands have been setting the standard for patient care for over eighty (80) years. Our products are trusted by medical professionals in university medical centers, hospitals, private practices, clinics and research laboratories around the world. Natus does not endorse personal/non-work related comments made by employees on social media. Further, Natus values the respect and inclusion of all people without regard to race, color, religion, sex, national origin, veteran status, disability, sexual orientation, gender identity, or any other protected status.

Nectero Medical is a clinical-stage biotech company pioneering novel therapies with a potential to treat aneurysmal disease and improve patients' lives.

Neocis, the first dental robotics company, is committed to enhancing dental surgeons’ capabilities and advancing patient care. Or Yomi is bringing the power of surgical robotics to dentistry.

At Neuralace Medical, we are driven to accelerate the world's transition to sustainable, non-invasive chronic pain relief. What do we believe that very few others do? We fundamentally believe that overcoming chronic pain is inevitable. With our bold vision, we are challenging the conventional thinking the healthcare industry is currently laden with to implement innovations and technological advances to improve the overall quality of life of individuals by maximizing pain relief and minimizing side-effects, redefining the very concept of pain therapy which can leave patients with more side-effects than benefits. NeuraLace is not just a device developer, but also a technology company with a focus on medical innovations that can significantly restore the quality of life patients suffering from chronic pain. Our inherent interest in innovation and deep technical knowledge, along with the partnerships we are currently developing, will allow us to realize our vision and create something truly special. We are a startup medical technology company here to make a dent in the world of pain therapeutics!

Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.

NeuroBionics is pioneering the future of precision bioelectronic medicine by developing the next generation of implantable devices, designed to seamlessly interface with the human body. Our core technology lies in flexible, multifunctional fibers the size of a human hair, which can record and stimulate neural activity, deliver drugs, and ablate tissue. Using an endovascular approach, we will navigate our microscopic-sized flexible fiber implant through the intricate network of blood vessels to deliver precise therapeutic intervention to neural tissue. By making neural interfacing a minimally-invasive procedure, we will revolutionize deep brain stimulation and broaden access to this lifechanging therapy. By doing so, we aim to improve the lives of millions grappling with conditions like Parkinson's disease, essential tremor, epilepsy, and depression.

Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera's minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.

Northern Biomedical Research is a non-clinical research organization focused on targeted delivery of therapeutics using advanced techniques. Our team is experienced in providing industry-leading research for targeted-delivery of drugs, biologics, gene/cell therapies, and medical devices. With a strong regulatory history and scientific background in neuroscience, cardiovascular research, ophthalmology, and orthopedics, our team works closely with Sponsors to design a non-clinical program to exedite the regulatory process. For more information, stop by Booth 250. Â

NovoPedics, Inc. is developing implantable medical devices designed to relieve pain and restore mobility to patients suffering from severe meniscal injuries and meniscectomies. MeniscoFix™ is a polymer fiber-reinforced scaffold for total meniscus replacement designed to be gradually resorbed by the body and be replaced by new tissue. It represents an innovative approach to replace damaged meniscal tissue with a patented fiber-reinforced design similar to the native meniscus. It is designed to be attached to both soft tissue and bone, thus potentially enabling its use in total meniscus replacement surgery.

Noxilizer, Inc. provides ultra-low temperature (10°C to 30°C) nitrogen dioxide sterilization technology that offers many benefits over traditional sterilization methods. Noxilizer sells sterilization equipment to pharmaceutical, biotech and medical device manufacturers and also offers contract sterilization services at its Baltimore, MD facilities. Noxilizer’s expert microbiology and material compatibility team is ready to partner to solve sterilization challenges through every phase of the process. To learn more about Noxilizer’s contract sterilization services or sterilization equipment please email info@noxilizer.com or visit www.noxilizer.com

Octagos Health is a dynamic and rapidly growing healthcare technology company dedicated to improving patient outcomes through AI-driven solutions. Octagos provides a cloud-based platform that aggregates remote and in-person device interrogations for all cardiac rhythm management (CRM) manufacturers, wearables (Holter, MCT, etc.) and remote physiologic monitoring (RPM).

Onkos Surgical is a privately held, specialty medtech company founded in 2015 that uses a digital platform and patient imaging analysis, to reconstruct bones following cancer therapy using personalized surgical planning and 3D printing.

A Chicago-based medical device development firm partnering with entrepreneurs, startups and large organizations worldwide to bring their innovations to life.

Orchestra BioMed biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine.

Organoid Therapeutics is developing organoid-based technologies to correct hormone deficiencies in patients and streamline drug discovery and toxicology testing in the lab.

Orthobond is an antimicrobial technology company that has developed proprietary antimicrobial nanosurfaces, with broad applications in the medical device industry and more such as commercial, industrial, automotive, and beyond. We’re the first company to utilize nanoscale surface modifications that can be permanently bound to any surface, killing bacteria, viruses, and fungi by mechanically rupturing pathogens without using antibiotics.

Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, we deliver exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH™ navigation system. 𝗢𝘂𝗿 𝗩𝗶𝘀𝗶𝗼𝗻: To be the unrivaled partner in MedTech, delivering exceptional experiences and life-changing solutions. 𝗢𝘂𝗿 𝗠𝗶𝘀𝘀𝗶𝗼𝗻: We provide medical technologies that heal musculoskeletal pathologies. We enable our teams through opportunities for growth, ownership of responsibilities, and empowerment to execute. We do this for patients and the healthcare professionals who treat them. We collaborate with world-class surgeons and other partners to bring to market highly innovative, cost-effective, and user-friendly medical technologies through excellent customer service. We do this to improve people’s quality of life and, in doing so, create exceptional value for our customers, employees, and stockholders. 𝗢𝘂𝗿 𝗩𝗮𝗹𝘂𝗲𝘀: • Take Ownership • Innovate Boldly • Win Together Join our mission to revolutionize musculoskeletal care and be a part of innovation that changes lives. Start your journey now at https://orthofix.com/about/careers/.

OrthoPediatrics is an Indiana-based bio-science company that designs and develops orthopedic implants and instruments for pediatric conditions.

Osseus is a pioneering medical device firm focused on developing advanced technology products for the minimally invasive spine surgery theatre. Our teams of forward-thinking surgeons, bright-minded engineers and visionary product managers design systems aimed at enhancing patient outcomes and changing healthcare for the better. Our Values Excite: We inspire excitement by developing next generation systems. Envision: Our creative team envisions solutions to bring innovative ideas to life. Evolve: We continually evolve our portfolio of products to stay ahead of the curve. Our Difference As an organically funded, privately held medical device pioneer, Osseus is not bound by corporate bureaucracy or shareholder demands. We have the freedom to explore new possibilities, experiment with new technologies, and form close partnerships with surgeons to develop groundbreaking answers to surgical questions. Using advanced materials and leading-edge technologies like additive manufacturing, we are creating modern, inventive devices that help solve anatomic challenges and push patient outcome boundaries. Our History After working in the medical device industry for decades, our founders decided it was time to do things differently. What started as a collection of next-generation ideas, has become an innovative medical device firm with the freedom to explore novel concepts, partner with entrepreneurial surgeons, and develop leading-edge spinal systems. At Osseus, creative minds are always at work. #SpineIndustry #MedicalDevices #Healthcare #SpineImplants #3DPrinting #AdditiveManufacturing

Ossio is an orthopedic medical device company founded in Israel in 2014 with the vision to completely transform the orthopedic experience for physicians, patients, and payors. Ossio's mission is to replace metal implants as the standard of care in the $10B+ orthopedic fixation market (screws, pins, plates) with an intelligent bone regeneration technology. OSSIOfiber™ represents a breakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore mobility with nothing permanent left behind. Our products have the mechanical strength needed for easy insertion and secure fixation while enabling the body to regrow bone, completely incorporating and replacing the implant without the adverse inflammation and weakness often seen in “bio-resorbables”.

Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections.

CONNECTING THE HUMAN BRAIN What if we could restore or enhance function using the power of AI and advanced technology? Our direct data interface enables this connection. MISSION We are building a high data-rate brain computer interface (BCI) to provide technology solutions for people with neurological and brain-related conditions. Our first clinical application will help severely motor-impaired people communicate, enabling social connection and restoring independence. ABOUT Paradromics was founded in 2015 by a team of engineers and neuroscientists, received early support from both NIH and DARPA, and is currently backed by venture capital.

Paragon 28 was established in 2010 as an orthopedic foot and ankle company. The name "Paragon 28" was chosen to show that we are exclusively a foot and ankle company, with the "28" representing the number of bones in the foot. We will remain true to that vision. Paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. Our mission is to strategically build a company around the core principles that drive innovation and quality. Relentlessly working to advance the science behind foot and ankle surgery, Paragon 28 is passionate about and committed to: - Creation and Innovation: Blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - A Focus on Service: A customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - Efficient Practices: Meeting the needs of increasing pricing pressures and reimbursement while continuing to develop cutting-edge surgical implants. - Practical and Comprehensive Solutions: Creating complete surgeon-centric systems, specialty instruments, and next generation implants to solve real world issues faced by foot and ankle surgeons. - Research Motivated: Improving clinical outcomes through meaningful and unbiased research. We are ready to embrace research data regardless of marketing impact. Motivation, competition and the desire to learn are unique characteristics that are incredibly valuable to our success. Paragon 28's work environment is modern and exciting. We are seeking experienced and energetic individuals to join our team in areas of Quality, Engineering, Marketing, Sales, Administration and Accounting.

Penderia Technologies develops wireless technologies for orthopedic applications, with a focus on implantable sensors for monitoring injury and healing progress.

At Pera Labs, we develop digiceuticals and ai-powered solutions for difficult health problems such as fertility. The flagship component of our platform technology for fertility treatments is called SPERMAN, an artificial intelligence based sperm sorter system which provides automated solution for time consuming and labor intensive sperm assessment AND sperm selection procedures. SPERMAN helps fertility clinics perform highly accurate sperm assessment and separation in minutes not days. We take a holistic approach to fertility treatments. Therefore, starting from the assessment of sperm and egg cells all the way to newborn screening, our innovative platform technology can provide more efficient and affordable fertility treatment strategies. We are looking for investors, distribution and implementation partners. Join us for making fertility journey affordable and efficient.

Peytant Solutions, Inc. (PSI) is a medical device company, incorporating Regenerative Human Biomaterial   with  absorbable and alloy implant technologies. Our percutaneous, biologic AmnioStent...

The number of patients requiring hemodialysis is expected to reach 774,000 with an annual incidence of more than 160,000 new patients per year who require vascular access for hemodialysis. Vascular access for hemodialysis is creating a special pathway in the body to cleanse the blood when the kidneys aren't working (End Stage Renal Disease). Two methods of permanent vascular access: Arteriovenous Fistula (AVF) Arteriovenous Grafts (AVG) Phraxis, Inc is a Minneapolis MN based company that has developed the EndoForce™ Venous Anastomotic Connector to provide a procedural technique for AVG implantation that may lessen the neointimal hyperplasia-induced stenosis that is associated with conventional sutured venous anastomosis. See our complete clinical study of the EndoForce™ Venous Endovascular Anastomotic Connector here: https://pubmed.ncbi.nlm.nih.gov/36895157/ And join the movement at www.phraxis.com as we seek FDA approval. The EndoForce™ Venous Anastomotic Connector is an investigational device. Limited by Federal (United States) law to investigational use.

pH Sciences develops safe, innovative ingredients; manufactures those ingredients to exacting scientific and regulatory standards; and supplies those ingredients to dietary supplement and medical food companies who market finished products that are highly differentiated and effective.

Pinnacle Spine Group is dedicated to the design, development, manufacturing and marketing of innovative best-in-class spinal implants and instruments that offer greater opportunities for positive patient outcomes. We are committed to providing surgeons increased control, flexibility and choices when it comes to implants, instrumentation and autograft delivery, providing a better experience for surgeons and their staff so they can better serve their patients.

Ponte Biosciences, Inc. is a preclinical biotherapeutic company focused on developing a cell-based bioartificial liver system to treat acute forms of liver failure. The Company's Spheroid Reservoir Bioartificial Liver (SRBAL) system was developed at the Mayo Clinic and utilizes metabolically active primary hepatocytes (liver cells) to replace and/or supplement liver function for patients with liver failure being treated in the Intensive Care Unit (ICU).

Precision Medical Technologies, Inc. is a contract manufacturer of orthopedic implants and instruments with a focus on spine, extremities, trauma and sports medicine. We are ISO 1 3485:2003 Certified. The business is divided into two separate operating Divisions; Implant Manufacturing and Instrument Manufacturing with both segments being staffed with their own Quality Engineering, Production Engineering, and Operating Management. The Instrument Division operates out of the Warsaw and Rome City facilities, while the Implant Division is only located at the Warsaw facility. The Implant Division's strategy is to minimize variation in the manufacturing process to drive high quality performance. The primary objective is to reduce or eliminate job changes, manufacture on dedicated equipment, and complete the implant production in one operation. Statistical monitoring of the process provides our Engineers with the data to continually improve quality and productivity. The Instrument Division's business is truly a job shop environment with normal order quantities of 1 0, 20, or 50 units with multiple components. This product mix requires constant changes or set-ups on CNC equipment; the low volumes require 1 00% check of critical dimensions at the machine. The concentration of effort in this business is in the areas of consistent machine set-ups and high quality efficient production on the back shifts.

Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from neurological illnesses. We are building the only brain–computer interface that is designed to be minimally invasive, safely removable, and capable of processing large amounts of data.

Presbia is a medical device company focused on the development of the presbyopia-correcting Presbia Flexivue Microlens™ – an innovative solution for the common age-related loss of the ability to read or focus on near objects. The 3mm diameter lens is implanted in a corneal pocket created by a femtosecond laser.

Profusa's mission is to make our body's chemistry easily accessible to improve health and wellness. We are dedicated to becoming a leader in the development of real-time biosensors that provide unprecedented insights into our overall health status. We are leading the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Our technology enables the development of bioengineered sensors that become one with the body to detect and continuously transmit actionable, medical-grade data for personal and medical use. Profusa's first clinical offering, the Lumee Oxygen Platform™, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. It may be used in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery. Any questions? Please visit profusa.com or email us at info@profusa.com

R3 Vascular is a privately-held Medical Device company that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds (BVS) with a sirolimus coating for the treatment of peripheral artery disease (PAD) below the knee. PAD is the narrowing or blockage of the vessels that carry blood from the heart to the legs or lower extremities; it is primarily caused by the buildup of fatty plaque in the arteries, which is called atherosclerosis. PAD can happen in any blood vessel, but it is more common in the legs than the arms. It affects 200 million people globally. Approximately 6.5 million people at the age of 40 and older in the United States have PAD. These numbers continue to rise given the increasing burden of risk factors and an aging population. If a patient has PAD, they are at risk for developing coronary artery disease and cerebrovascular disease, which could lead to a heart attack or stroke as well. The R3 Vascular BVS platform combines the best of both worlds of BTK therapy, designed to deliver the ‘stent-like' support of a scaffold, along with the anti-inflammatory result of sirolimus, but ‘disappearing' over time as the vessel heals. R3 Vascular is headquartered in Mountain View, Calif., USA, with additional operations in Munich, Germany.

Collaborative robots have reshaped automation by enabling a wide spectrum of new applications in different industries – but a significant dexterity gap still remains even with these robots. Manipulation of delicate, fragile, or brittle items is still out of reach for robots. Inspired by our human fingertips which provide unmatched dexterity, we have set out to reduce this gap by adding tactile sensing similar to the sensing in our fingertips to enable robotic manipulation of more delicate items. Introducing the Tactile Fingertip. Ras labs has combined material science innovation with data science and precision engineering to provide the first state of the art, Tactile Fingertip for robotic gripper fingers. Our sensor is based on our patented Electroactive Polymer which can be fabricated in many configurations. Both squishy and a level of firmness. Think our revolutionary technology could help your business? Send us a message. We'd love to chat!

The Next Generation of Branched Aortic Stent Grafts A challenging frontier for aortic endovascular repair, complex aortic aneurysms are those involving the take-offs of major arterial branches or short landing zones. Through its patented technology, Red Vascular Technology meets this challenge with the next generation of non-modular branched endografts. Red Vascular Technology, LLC is currently involved in the development of minimally invasive techniques for the treatment of Aortic aneurysms of both the Abdominal and Thoracic Aorta which involve the major branch origins of these vessels. The current state of the art for the treatment of aneurysmal disease which effects the origins of the major branches is the use of "Fenestrations" including Periscope, or Chimney techniques of the endograft and construction of the device in-situ. All these techniques are Modular in nature which means that there are multiple parts of the endograft which must be deployed separately. This increases the complexity, complications and in general the outcomes of such devices. The Red Vascular Technology design and intellectual property allows the branch or branches to be non-modular and therefore the endograft is deployed in "one piece". This technology allows for less complications which in turn significantly increases patient safety and reduces cost.

Regenerative Patch Technologies LLC (RPT) is a CA-based biotechnology company focused on the development of stem cell-based therapies designed to reverse blindness caused by advanced dry age related macular degeneration (AMD).

Developing surgical solutions to improve peripheral nerve repair: - Accelerating healing following a nerve injury - Improving nerve function following injury and repair

ReShape Lifesciences Inc. is America's premier weight-loss and metabolic health-solutions company, offering an integrated approach to managing and treating obesity. The FDA-approved Lap-Band® program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The recently launched 𝗋𝖾𝗌𝗁𝖺𝗉𝖾𝗰𝗮𝗿𝗲™ virtual health coaching program is a reimbursed, virtual tele-health, weight-management program that supports lifestyles changes for al weight-loss patients, to help them keep the weight off over time. Together, we will build a healthy life, one choice at a time.

restor3d enables surgeons to improve the reconstruction and repair of the human body through 3D printed implants with enhanced anatomical fit and superior integrative properties. Leveraging expertise and experience in 3D printing of key biomedical materials spanning a wide range of properties, restor3d seeks to improve medical device solutions.

RevBio was started with one goal in mind—to end medicine's 50 year search for a biocompatible bone adhesive. Effective for bone-to-bone as well as bone-to-metal wet field applications, Tetranite® is a revolutionary biomaterial that promises to transform bone repair—for both patients and clinicians. Inspired by the marine animal the sandcastle worm, Tetranite is simple chemistry. Bioengineered from the worm's secreted protein, our synthetic adhesive is the only patented biomaterial which satisfies both the required and desired properties for a bone adhesive: wet field performance, multi-surface bonding, rapid mechanical stability, and controlled biodegradability. The properties of Tetranite™ include the ability to provide immediate fixation of bone to bone and bone to metal. This adhesive has been shown in multiple animal studies to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices. Existing data has also shown that Tetranite™ is reabsorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth over time.

Rice University is a Higher Education institution that offers a range of undergraduate and graduate programs, and is known for its research initiatives.

RTI Surgical (RTI) is a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine. We are expert partners to Original Equipment Manufacturers (OEMs), working with them to identify clinical problems and develop customized solutions that promote healing, accelerate recovery, and help prevent complications. We focus on specialized clinical segments, including breast and plastic surgery, sports medicine and orthopedics, and neuro and spine surgery. Our Mission is to enhance patients' lives by creating the best clinical outcomes through innovative, high-quality medical solutions.

RxSight® is an ophthalmic medical technology corporation headquartered in Aliso Viejo, California that has commercialized the world’s first and only adjustable intraocular lens (IOL) that is customized after cataract surgery. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye.

Currently, SafetyFix is the one and only FDA approved removable bone screw on the market with patents in the US, Europe, Canada, China, & Australia. The SafetyFix EasyOut Removable Bone Screw can be used for bone fracture repair and other surgical procedures involving the foot, hand, wrist, ankle, elbow and other small bone corrective procedures. We believe no one should live with metal hardware in their body, which is why we have created the solution.

Samsara Vision, Inc. is a privately held specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. Our lead product, the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), is the first FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD) – End-Stage AMD. End-Stage AMD is the leading cause of blindness in older Americans. Our goal is to help patients reconnect to the things in life they love to see and do. To help achieve this, we will establish a high level of collaboration with our healthcare provider customers through a broad range of direct support programs and services.

At Satellite Bio, we’re on a journey – a quest to treat some of the most elusive diseases known to humankind by pioneering Tissue Therapeutics, an entirely new category of regenerative medicine. With the first-of-its-kind SAT (Satellite Adaptive Tissues) platform, Satellite Bio can turn virtually any cell type into bioengineered tissues that are integrated into the body to restore natural function. These tissues, called Satellites, can deliver the comprehensive cellular response needed to repair or even replace critical organ functions in patients with diseases caused by the interaction of genetic and environmental factors. The SAT platform is an unprecedented technology with the potential to drive a pipeline of sophisticated cell-based therapeutic solutions that tackle a broad range of elusive diseases. Satellite Bio’s quest is as audacious as it is clear: bring new hope to patients and families suffering from elusive diseases. Tissue Therapeutics is how it will deliver on that promise—and why it is deeply committed to leading and realizing the potential of this exciting new frontier in regenerative medicine.

Sayenza Bio is a leading clinical stage biotechnology company committed to improving patient lives by harnessing the regenerative power of fat, the body’s largest source of stem cells, for limitless aesthetic and regenerative medicine applications. At Sayenza, our passionate, doctor-driven team unites cutting-edge scientific innovation with vast commercial expertise, propelling us towards transformative breakthroughs in healthcare. With a strong leadership team in place, extensive publications in leading journals, and top-tier KOLs signing up as early adopters, NESVF™ and Liquid Gold Graft™ are poised to become gold standards for stem cell and fat grafting applications and take a large chunk of the $6.25 billion aesthetics market.

Second Heart Assist Inc. is a medtech startup company that will revolutionize the treatment of chronic heart failure (HF). With its novel aortic stent pump technologies, Second Heart will enhance the lives of millions who suffer from chronic HF worldwide.

Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM"​) system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life. The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies. Our highly pure insulin-producing cells are micro-encapsulated through a proprietary technology that enables the function of human pancreas cells in type-1 diabetes models without the need for immuno-suppression. Seraxis intends to bring SR-01 to the clinic in order to provide a cure for the devastating disease of diabetes.

ShiraTronics is a forward-thinking medtech startup committed to revolutionizing the field of migraine medicine with our minimally invasive neuromodulation system. Our mission? To transform the lives of those facing Chronic Migraine by reducing headache days and restoring quality of life.

The simplicity of our design--born out of our extensive experience--comes down to the basic notion that traditional fixation techniques aren't strong enough and don't last. Our InSet™ approach to Glenoid fixation is revolutionizing shoulder arthroplasty and, more importantly, improving procedure longevity--ultimately changing patient's lives.

We are reimagining eyecare with transformative technology and an interventional mindset. We believe interventions should happen sooner to preserve, protect, or restore natural eye function. So, we aim to provide eyecare providers with transformative, clinically-proven therapies that are intuitive, less invasive, and more intelligent.

SigmaGraft®, based in Fullerton, California, USA, collaborates with the world's leading clinicians and researchers to innovate products and build clinical experience. Our products are registered and sold worldwide, and they include bone grafting products for bone regeneration, membrane products for tissue regeneration, and more.

Silony Spine is disrupting the spinal surgery marketplace with compatible options for enabling technology systems. Check out our portfolio of precision tools and hardware that add significant value and freedom of choice.

Silver Bullet Therapeutics is an early stage company dedicated to the treatment of osteomyelitis. Through the use of proprietary implants that can be placed using local anesthesia and minimal sedation, the duration of exposure to long-term intravenous antibiotic will be shortened.

Simplify Medical is a medical devices company specializing in clinically effective spine technology for the cTDR procedure segment.

SINTX Technologies is an OEM ceramics company that develops and commercializes advanced ceramics for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of advanced ceramics for external partners.

Autogenoues livestock vaccines and bacterins

Founded in 2003, Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.

Spineology's OptiMesh is the only conforming, patient specific lumbar expandable implant on the market. OptiMesh is delivered through the smallest insertion profile, dynamically conforms to a patient’s unique endplate morphology, and powerfully expands to one of the largest implant footprints available. Spineology’s OptiMesh features our unique Conform and Expand™ technology, enabling a custom anatomical fit for lumbar fusion surgical patients. OptiMesh is designed to overcome the challenges of static and mechanically expandable implants.

SpineSmith designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. We take a different approach from other companies, utilizing a collaborative process between engineers and spine surgeons. This approach results in the development of truly innovative biological and hardware technologies for use in the treatment of patients with spinal disorders. Our unique, think-tank philosophy gives spine surgeons the ability to directly impact the direction of our product portfolio, ensuring applicability and the highest possible standards of quality.

SpineSource is commencing the U.S. launch of the CATAMARAN™ SIJ Fusion System, patented and manufactured by Tenon Medical, Inc. (Los Gatos, CA). The titanium CATAMARAN™ SIJ engages the ilium and sacrum via a posteroinferior approach with two fenestrated pontoons joined by an osteotome bridge spanning the joint.  It's pontoons and bridge are packed with autograft harvested off the drill bit used to prepare the joint. Just one implant is required. This posteroinferior approach targets the dense aspect of the joint. It's entry point, angle and trajectory point away from critical neural and vascular structures. The Mission of SpineSource is to provide implant devices, service and expertise using the highest ethical standards to benefit hospitals and surgeons, assisting them to promote the healing and well-being of patients with spinal disorders.

SPR Therapeutics is a medical device company focused on non-opioid, non-surgical, minimally invasive pain management solutions. The company is dedicated to improving the lives of individuals living with acute and chronic pain through innovative treatments that aim to provide meaningful relief without the need for opioids or surgery. The primary product offered by SPR is the SPRINT PNS System, a neuromodulation treatment that delivers significant and sustained relief from chronic pain. This system is a first-line peripheral nerve stimulation option that reconditions the central nervous system without requiring permanent implants or risking addiction. It is cleared for use up to 60 days and has been studied for various pain conditions, including low back pain and post-operative pain. Headquartered in Cleveland, Ohio, with additional offices in Chapel Hill, North Carolina, and Minneapolis, Minnesota, SPR has a senior management team with extensive experience in the pain management and MedTech sectors. The company has been recognized as the fastest-growing private company in Northeast Ohio, reflecting its rapid growth and influence in the medical device industry.

STAAR Surgical Company (an S&P 400 midcap company trading under NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 35 years. The company offers the EVO Visian implantable Collamer® lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer Lens or "ICL"​. Over 1,00,000 Visian ICLs have been implanted to date. It also provides minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; nanoFLEX IOL, a single piece Collamer aspheric optic; and Toric IOLs for cataract patients, as well as preloaded injectors for use in cataract surgery. In addition, the company sells surgical products, and other related instruments and devices, as well as injector parts; and manufactures AquaFlow devices for the treatment of glaucoma. It markets its products to health care providers, including surgical centers, hospitals, managed care providers, health organizations, group purchasing organizations, and government facilities primarily under the STAAR, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, Epiphany, and AquaFlow trademarks. The company sells products directly through its sales representatives and independent distributors in more than 75 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Lake Forest, California. Its manufacturing plant is located in Monrovia, CA.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2023 Sales: $20.5 billion ● Industry: Medical Instruments & Supplies ● Employees: 52,000 worldwide ● 40 years of sales growth leading up to 2020 ● 44+ Manufacturing and R&D Locations Worldwide ● $1.4 billion spent on research and development in 2023 ● ~12,900 patents owned globally in 2023 ● Products sold in ~75 countries ● Fortune 500 Company ● 7 consecutive years as one of Fortune's World's Best Workplaces Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296

Subsense is a neurotechnology company developing the first non-surgical, nanoparticle-based bidirectional brain-computer interface. Subsense is partnered with leading global neurological research institutions. The company is venture-backed with its global headquarters in Palo Alto, California.

Swan NeuroTech is a Pittsburgh-based startup developing biodegradable implants for peripheral nerve injuries.

Synapse Biomedical Inc (SBI) was founded in September 2002 to commercialize the NeuRx Diaphragm Pacing System (DPS)® that has been developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland. The innovative research performed at these institutions has led to significant advances in the state of the art of electrical stimulation for the treatment of chronic respiratory insufficiency. This innovation allows the technology to meet clinical needs, beyond the ability of the currently available systems, in Spinal Cord Injuries, in the diaphragm conditioning in muscular dystrophies (such as ALS) and in respiratory short-term intensive care settings.

SynCardia Systems, LLC, a Picard Medical Company, is headquartered in Tucson, AZ. SynCardia sells the world's first and only US Food and Drug Administration (FDA) and Health Canada approved total artificial heart as bridge to transplant for patients suffering from biventricular heart failure The SynCardia Total Artificial Heart is available in two sizes to accommodate patients’ diverse physiologies. The Freedom Portable Driver™ allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant. The SynCardia Total Artificial Heart has been successfully used in over 2,000 patients and is the most widely used and extensively studied total artificial heart in the world. For additional information and label information, visit us at www.syncardia.com.

INNOVATIVE BONE GRAFTS BASED ON IMPROVED BIOACTIVE GLASS Synergy has identified an optimal bioactive glass particle with a spherical shape and a biomodal size range that has been shown to significantly improve bone healing. Synergy's BioSphere® particles have been engineered to maximize the bone healing potential of bioactive glass. Synergy Biomedical is a privately-held medical device company focused on bringing biomaterial based products to the orthopedic and spinal surgery markets. Synergy's BIOSPHERE Technology represents an innovative approach to advancing bone graft technology, and improving bone healing and patient outcomes. Synergy Biomedical welcomes inquiries from independent sales distributors with an understanding of orthopaedic and spinal surgery. We are looking for distributors with a proven track record who are willing to grow our bone graft market. Please visit our website for more information: www.synergybiomedical.com

Repair Mesh

Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a Takara Bio company, develops, manufactures, and distributes a wide range of life science reagents under the Takara®, Cellartis®, and Clontech® brands. Our products support applications including stem cell research; NGS; gene discovery, regulation, and function studies; protein expression and purification; RNAi and gene editing; and plant and food research.

The company is developing a ventricular shunt, for children with hydrocephalus.

Delivering the latest innovation in sacroiliac joint surgical solutions, Tenon Medical is uniquely positioned to introduce a refined surgical option for patients with chronic sacroiliac joint pain that fail conservative care. The Catamaran™ SIJ Fusion System offers a patented new surgical solution that places a single implant directly into the SI joint. Tenon Medical is led by a powerful team with years of cumulative experience in designing and launching innovative surgical solutions that deliver a pathway to improved quality of life for thousands of patients.

Tissue Regeneration Systems™ (TRS™) is a start-up medical device company commercializing a breakthrough skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Our technology addresses a broad range of clinical applications, and has been validated by comprehensive University, NIH and company-sponsored research initiatives spanning a period of well over a decade. NOVEL 3D PRINTED RESORBABLE SCAFFOLDS TRS has a proven capability to fabricate complex, patient specific, load- bearing resorbable implant solutions using 3D printing methods. UNIQUE BIOACTIVE MINERAL COATING Our proprietary mineral coating, Affinity™, exhibits unique bioactive properties that can be applied to our resorbable scaffolds, as well as to conventional orthopedic and spine implants. The Affinity morphology is a plate-like nanostructure, which mimics the mineral structure of native bone, and modulates the biologic environment in a manner not previously exhibited by other implant coatings. SCALABLE FDA COMPLIANT MANUFACTURING TRS has established a fully independent, FDA-compliant manufacturing facility with a certified cleanroom. Our operation can support commercial product volumes. FDA CLEARANCE Both our 3D printed resorbable scaffold technology and our Affinity mineral coating have received FDA 510(k) clearance. STRONG INTELLECTUAL PROPERTY AND TRADE SECRET POSITION TRS has an extensive patent portfolio and has also accumulated a number of important trade secrets in perfecting our technology and fabrication methods. Together, this creates meaningful protection and exclusivity for our technology platform.

Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, these bioengineered stem cell-derived tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs.

TRIA’s core competencies encompass the discovery and research of immune-based therapeutics. Developing vaccines for influenza, nicotine, and more.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.

Uptake Medical® developed innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor®, was the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any foreign materials in the lung. Uptake Medical was acquired in July 2016 by Uptake Medical Technology Inc, a subsidiary of Broncus Holding Corp.

Vascular Perfusion Solutions (VPS), a Texas-based early-stage Medtech company, is revolutionizing organ transplantation with a focus on simplicity, ease of use, and accessibility in price through our flagship product, the VP.S ENCORE®, a hypothermic machine perfusion device for prolonged cardiac graft preservation. This innovative device represents a groundbreaking advancement in heart preservation technology, surpassing conventional methods such as the ice-cooler. It has gained FDA breakthrough device designation in 2021 and undergone successful preclinical testing on over 100 hearts, including ovine, porcine, and human hearts donated for research.

Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogen™, an investigational sirolimus formulation for local, perivascular drug delivery. Sirogen™ is currently undergoing clinical trials to determine its safety and effectiveness in improving vascular access outcomes in patients requiring an arteriovenous fistula for hemodialysis.

At ViewRay, our vision is clear: conquer cancer by re-envisioning radiation therapy., giving doctors new and better ways to treat their patients. ViewRay®, Inc. (NASDAQ:VRAY) shifts the paradigm in cancer treatment with the MRIdian® MRI-guided adaptive radiotherapy system. We're changing radiation therapy for the better with accurate, precise and personalized cancer treatment that no other system delivers, addressing the key limitations of existing external-beam radiation therapy technologies. Real-time imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian shapes the dose to fit the day. It's the only MR solution that enables fully integrated adaptive treatment with complete, on-table re-optimization of the daily treatment plan. It knows when to strike – and when to stop. MRIdian is the only RT solution with automated beam gating for precise and accurate dosing. When the tumor moves, the beam stops. The result? Better outcomes for patients. After seven years of clinical use, MRIdian has treated more than 12,500 patients worldwide. We're an innovative, entrepreneurial company with big ambitions, unlimited potential and a passion for a culture that is diverse and committed to our physicians and their patients. If you're ready to change the way the world views cancer, come join our team.

Viscus Biologics was founded in 2012 to help companies solve complex challenges ranging from ideation to high volume production. We are specialists in natural polymer and extracellular matrix materials, with the ability to develop and manufacture highly-specialized components, devices, and products needed to restore tissue to a healthy, functioning, and durable state. A LIFE SCIENCE PARTNER Whatever biomaterial needs you may have, companies can depend on Viscus Biologics for succesful product realization, quality manufacturing and timely distribution. With over ten years of operating excellence, we are thoroughly experienced with established procedures, policies, and a quality system to support product realization. PROVEN PROCESS The established D4 (Define, Discover, Develop, Deliver) process ensures that components, devices, and products are successfully realized and optimized for high performance. ROBUST SUPPLY CHAIN Our robust and domestic centered supply chain and partner network ensures consistency, cost-containment, availability, and timely delivery of components, devices, and products.

Developing miniaturized, long-term biopharmaceutical implants to reduce medication adherence challenges.

The Wake Forest Institute for Regenerative Medicine is working to grow tissues and organs and develop healing cell therapies for more than 30 different areas of the body, from kidney and trachea to cartilage and lung.

GOAL: DISPRUPT AND TAKE OVER AN OLD AND OVERLOOKED $150 MILLION/YR. MARKET BY LEVERAGING OUR SUPERIOR AND CLINICALLY PROVEN DEVICE DESIGN WHY IS IT POSSIBLE? Current oral airways have been continually proven to be defective and studies have proven that these common airways are not adequate to maintain the oropharynx airway. Further, they are not designed to control the ever-problematic tongue. Even more, our studies showed that current oral airways possess no proportional dimensional standards in relation to how it would impact the oropharyngeal area. THE PROBLEM The biggest impediment, after placement of an oral airway, is the relaxation of the soft tissue structures in the hypopharynx. These structures are inclined to collapse, thus obstructing airflow, while occurring from both front-to-back and side-to-side, thus greatly decreasing the size of the oral opening. In relation, literally every patient before and after anesthesia, CPR, or sedation, is provided with a manual jaw-thrust to prevent the tongue from falling back and obstructing the airway. Furthermore, almost every patient intubated is provided with an airway to prevent biting of the soft endotracheal tube. Both of these procedures involve manually protracting the lower jaw by pulling it forward relative to the upper jaw. SOLUTION Studies have proven that mandibular advancement increases the oropharynx opening under anesthesia, but nobody designed that embodiment into an oral airway, or thought to design an airway to also control the tongue…until now. INTRODUCING OUR LOWER-JAW THRUST (LJT) ORAL AIRWAYS WHICH ARE ENGINEERED TO INCREASE THE OPENING OF THE OROPHARYNX AIRWAY & CONTROL THE TONGUE

Windmill Cardiovascular Systems has developed a new pumping paradigm to deliver synchronous, pulsatile, low-shear flow to support patients with end-stage heart failure. The Toroidal Ventricular Assist Device (TORVAD) has the potential to reduce the high adverse event rates associated with current VADs, which could improve the survival and quality of life for patients.

Xēnix Medical is a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery. The company, headquartered in Orlando, Florida, markets its line of spinal implant devices in the United States through a network of independent distributors.

The acquisition of Xeridiem Medical Devices by Spectrum Plastics Group was completed in September 2016. Please follow the Spectrum Plastics Group profile for future updates. https://www.linkedin.com/company/spectrum-plastics-group/

Xtremity is a premium medical device brand that develops advanced prosthetic socket technology.

Zavation Medical Products, LLC is a medical device company that designs, develops, manufactures and distributes medical device products that provide comprehensive medical solutions to improve and enhance quality of life for patients around the world. Dedicated to unparalleled patient care through innovative spinal solutions, vertically-integrated manufacturing, and world-class customer service.

Zeda is a leading technology solutions company. Our objective is to better lives by investing in cutting-edge technologies, innovative companies, and groundbreaking ideas. Our foundation combines expertise from diverse industries, including AM, nanotech, precision manufacturing, and incubating new ideas. From life-changing medical devices to the foremost advancements in space, our mission is to build it all better together.

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We advance our mission to alleviate pain and improve the quality of life for patients around the world with our innovative products and suite of integrated digital and robotic technologies leverage data, data analytics and artificial intelligence. Founded in 1927 and based in Warsaw, Zimmer Biomet has operations in more than 25 countries and sales in more than 100 countries. We maintain world-class scientific facilities and resources and collaborate with leading clinicians and researchers around the world. Awards and Recognitions • Forbes Best-in-State Employers in Indiana (2020 and 2021) • Newsweek's America's Most Responsible Companies (2021) • Military Friendly Employer by VIQTORY (2019 and 2020) • Best Employer Award: China (2011-2021) • Great Place to Work: Brazil (2021) • Indiana Manufacturers Association Manufacturing Excellence Awards (2020) • ComputerWorld's "Best Places to Work in IT" (2018-2020) • Forbes Global 2000 (2020 and 2021) • Fortune 500 List (2020 and 2021) • Medical Device and Diagnostic Industry MedTech Company of the Year (2019)

ZimVie is a global leader in dental implants and spine innovations. Advancing clinical technology foundational to restoring daily life.

ZSFab dedicates to produce high performance, low-cost, customized medical implants, surgical guides and anatomical models. We are developing unique solutions that integrate our own software tools, advanced modeling and optimization methods, and 3D printing technology. Each of us is born unique, and such uniqueness is imprinted in our DNA and reflected in our finger print, our face, our bone. Such uniqueness requires that when the part is worn, damaged, or aged, the replacement shall be the same. With the help of additive manufacturing, ZSFab is to structure, design, print the best medical implants and assist in the healing process. ZSFab has the goal to provide the solutions for health care, including surgical process. With the products of ZSFab, we will help to ease the burden of the doctors and release our customers of prolonged pain. In ZSFab, we believe: all men are created equal, but shall be treated differently, when it comes to healthcare.